Head-to-head comparisons of medication uses, side effects, warnings, and more.
Key takeaways
Amphetamine sulfate (Evekeo, Adzenys XR ODT) and Methylphenidate ER (Concerta, Ritalin LA) are both stimulants used to treat attention deficit hyperactivity disorder (ADHD), but they have some differences. Amphetamine sulfate is also approved for narcolepsy and short-term obesity treatment, while Methylphenidate ER is only approved for ADHD. Amphetamine sulfate comes in various forms, including tablets, dissolvable tablets, and liquids, whereas Methylphenidate ER is available in tablets, capsules, chewable tablets, and liquids. Both medications can cause side effects like trouble sleeping and loss of appetite, but Methylphenidate ER can also cause headaches and stomach pain. Amphetamine sulfate works by increasing norepinephrine, dopamine, and serotonin levels, while Methylphenidate ER mainly affects norepinephrine and dopamine. Both medications have a risk of misuse and dependence and are controlled substances. If you're pregnant or breastfeeding, it's important to discuss the risks and benefits of these medications with your provider.
Amphetamine (Evekeo)
Methylphenidate er
Amphetamine (Evekeo)
Methylphenidate er
Summary of Evekeo vs. Concerta
Summary for Stimulant
Prescription only
Immediate-release amphetamine, also known under the brand name Evekeo, is a stimulant. It's used to treat attention deficit-hyperactivity disorder (ADHD) in people 3 years and older. This medication can also help adults and some kids with narcolepsy. It's also approved to be used for a few weeks as an add-on treatment for obesity in people 12 and older. Immediate-release amphetamine comes as a tablet that you swallow with liquid. The dosage depends on why you're taking it and how well it works for you. Side effects can include loss of appetite and trouble sleeping. There are brand-name and generic versions. But there are special restrictions to get it because it's a controlled substance.
Summary for Stimulant
Prescription only
Methylphenidate extended-release (ER) is a first-choice option for people with attention deficit-hyperactivity disorder (ADHD). This once-daily medication can start to work within 2 hours and can last throughout the day. Methylphenidate ER can cause difficulty sleeping and a loss of appetite. It also has a potential risk of misuse and dependency and is thus a controlled substance.